Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.
FDA application actionNovember 12, 2025
Acyclovir
Approved submission · SUPPL 28
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionNovember 12, 2025
Acyclovir
Approved submission · SUPPL 21
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionNovember 6, 2025
Dasatinib
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 30, 2025
Everolimus
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 15, 2025
liraglutide
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 14, 2025
liraglutide
Approved submission · SUPPL 26
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 14, 2025
liraglutide
Approved submission · SUPPL 46
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 14, 2025
liraglutide
Approved submission · SUPPL 22
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 30, 2025
Dasatinib
Approved submission · SUPPL 2
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 25, 2025
Tirzepatide
Approved submission · SUPPL 34
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 25, 2025
Tirzepatide
Approved submission · SUPPL 31
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 19, 2025
propofol
Approved submission · SUPPL 36
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 28, 2025
Dasatinib
Approved submission · SUPPL 10
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 28, 2025
Dasatinib
Approved submission · SUPPL 11
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 28, 2025
Dasatinib
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 28, 2025
Dasatinib
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 27, 2025
Dasatinib
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 27, 2025
liraglutide
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 25, 2025
Dasatinib
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 12, 2025
propofol
Approved submission · SUPPL 46
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 1, 2025
Dasatinib
Approved submission · SUPPL 5
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 22, 2025
liraglutide
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 21, 2025
Everolimus
Approved submission · SUPPL 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 21, 2025
Everolimus
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →